> top > projects > Inflammaging > docs > PubMed:17965424 > annotations
Inflammaging  

PubMed:17965424 JSONTXT 27 Projects

Annnotations TAB TSV DIC JSON TextAE Lectin_function IAV-Glycan

Id Subject Object Predicate Lexical cue
T1 0-189 Sentence denotes Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).
T1 0-189 Sentence denotes Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).
T2 190-200 Sentence denotes OBJECTIVE:
T2 190-200 Sentence denotes OBJECTIVE:
T3 201-377 Sentence denotes A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).
T3 201-377 Sentence denotes A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).
T4 378-399 Sentence denotes PATIENTS AND METHODS:
T4 378-399 Sentence denotes PATIENTS AND METHODS:
T5 400-569 Sentence denotes A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).
T5 400-569 Sentence denotes A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).
T6 570-634 Sentence denotes Use of gastroprotective agents and low-dose aspirin was allowed.
T6 570-634 Sentence denotes Use of gastroprotective agents and low-dose aspirin was allowed.
T7 635-791 Sentence denotes The prespecified primary end point consisted of the cumulative rate of patient discontinuations due to clinical and laboratory GI adverse experiences (AEs).
T7 635-791 Sentence denotes The prespecified primary end point consisted of the cumulative rate of patient discontinuations due to clinical and laboratory GI adverse experiences (AEs).
T8 792-885 Sentence denotes General safety was also assessed, including adjudicated thrombotic cardiovascular event data.
T8 792-885 Sentence denotes General safety was also assessed, including adjudicated thrombotic cardiovascular event data.
T9 886-988 Sentence denotes Efficacy was evaluated using the Patient Global Assessment of Disease Status (PGADS; 0-4 point scale).
T9 886-988 Sentence denotes Efficacy was evaluated using the Patient Global Assessment of Disease Status (PGADS; 0-4 point scale).
T10 989-997 Sentence denotes RESULTS:
T10 989-997 Sentence denotes RESULTS:
T11 998-1144 Sentence denotes Mean (SD; maximum) duration of treatment was 19.3 (10.3; 32.9) and 19.1 (10.4; 33.1) months in the etoricoxib and diclofenac groups, respectively.
T11 998-1144 Sentence denotes Mean (SD; maximum) duration of treatment was 19.3 (10.3; 32.9) and 19.1 (10.4; 33.1) months in the etoricoxib and diclofenac groups, respectively.
T12 1145-1333 Sentence denotes The cumulative discontinuation rate due to GI AEs was significantly lower with etoricoxib than diclofenac (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI:
T12 1145-1333 Sentence denotes The cumulative discontinuation rate due to GI AEs was significantly lower with etoricoxib than diclofenac (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI:
T13 1334-1359 Sentence denotes 0.47, 0.81; p<or=0.001)).
T13 1334-1359 Sentence denotes 0.47, 0.81; p<or=0.001)).
T14 1360-1615 Sentence denotes The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).
T14 1360-1615 Sentence denotes The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).
T15 1616-1745 Sentence denotes Etoricoxib and diclofenac treatment resulted in similar efficacy (PGADS mean changes from baseline -0.62 vs -0.58, respectively).
T15 1616-1745 Sentence denotes Etoricoxib and diclofenac treatment resulted in similar efficacy (PGADS mean changes from baseline -0.62 vs -0.58, respectively).
T16 1746-1758 Sentence denotes CONCLUSIONS:
T16 1746-1758 Sentence denotes CONCLUSIONS:
T17 1759-1890 Sentence denotes Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg.
T17 1759-1890 Sentence denotes Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg.
T18 1891-2029 Sentence denotes Discontinuations from renovascular AEs, although less common than discontinuations from GI AEs, were significantly higher with etoricoxib.
T18 1891-2029 Sentence denotes Discontinuations from renovascular AEs, although less common than discontinuations from GI AEs, were significantly higher with etoricoxib.